Adagene (ADAG) Long-Term Investments (2019)

Adagene (ADAG) posted quarterly Long-Term Investments of $2.5 million for Q4 2019.

Adagene (ADAG) Long-Term Investments (2019) Analysis & Trends

Adagene (ADAG) has reported Long-Term Investments for 1 consecutive years, with $2.5 million the latest figure, recorded in Q4 2019.

In Q4 2019, Long-Term Investments changed N/A year-over-year to $2.5 million; the TTM figure through Dec 2019 stood at $2.5 million (changed N/A YoY), while the FY2019 annual figure was $2.5 million, changed N/A from the prior year.
Long-Term Investments steadied at $2.5 million in Q4 2019 per ADAG's latest filing.
Across five years, Long-Term Investments topped out at $2.5 million in Q4 2019 and bottomed at $2.5 million in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	372.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.17 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Adagene	310.54 Mn	310.54 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	2.51 Mn